User of angiotensin-converting-enzyme inhibitor and/or angiotensin II receptor blocker might be associated with vascular calcification in predialysis chronic kidney disease patients: a retrospective single-center observational study : ACEI/ARB and vascular calcification.
ACE inhibitor
ARB
Angiotensin II
Vascular calcification
Journal
BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793
Informations de publication
Date de publication:
06 01 2021
06 01 2021
Historique:
received:
07
05
2020
accepted:
30
11
2020
entrez:
7
1
2021
pubmed:
8
1
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Vascular calcification is a prominent feature in chronic kidney disease (CKD) and diabetes mellitus. A recent report suggests that angiotensin II is protective to vascular calcification. Therefore, we investigated the relationship between vascular calcification and use of angiotensin-converting-enzyme inhibitor (ACEI) and/or angiotensin II receptor blocker (ARB) from a cross-sectional view. A total of 121 predialysis CKD patients (age 71 ± 12 y; male 72; estimated glomerular filtration rate (eGFR) 20.2 (11.8 - 40.3) mL/min/1.73 m The Calc/BSA was 5.62 (2.01 - 12.7) mL/m ACEI/ARB user was associated with vascular calcification in predialysis patients with low eGFR. Prospective studies with larger numbers of patients or more in vitro studies are needed to confirm whether this phenomenon is due to the use of ACEI/ARB itself, the underlying disease condition or the prescription bias.
Sections du résumé
BACKGROUND
Vascular calcification is a prominent feature in chronic kidney disease (CKD) and diabetes mellitus. A recent report suggests that angiotensin II is protective to vascular calcification. Therefore, we investigated the relationship between vascular calcification and use of angiotensin-converting-enzyme inhibitor (ACEI) and/or angiotensin II receptor blocker (ARB) from a cross-sectional view.
METHODS
A total of 121 predialysis CKD patients (age 71 ± 12 y; male 72; estimated glomerular filtration rate (eGFR) 20.2 (11.8 - 40.3) mL/min/1.73 m
RESULTS
The Calc/BSA was 5.62 (2.01 - 12.7) mL/m
CONCLUSIONS
ACEI/ARB user was associated with vascular calcification in predialysis patients with low eGFR. Prospective studies with larger numbers of patients or more in vitro studies are needed to confirm whether this phenomenon is due to the use of ACEI/ARB itself, the underlying disease condition or the prescription bias.
Identifiants
pubmed: 33407242
doi: 10.1186/s12882-020-02198-6
pii: 10.1186/s12882-020-02198-6
pmc: PMC7789142
doi:
Substances chimiques
Angiotensin Receptor Antagonists
0
Angiotensin-Converting Enzyme Inhibitors
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
7Références
Calcif Tissue Int. 2013 Oct;93(4):365-73
pubmed: 23456027
Am J Physiol Endocrinol Metab. 2004 May;286(5):E686-96
pubmed: 15102615
NDT Plus. 2009 Jun;2(3):259-60
pubmed: 25984006
PLoS One. 2015 Apr 13;10(4):e0122691
pubmed: 25874620
Clin Chem. 1972 Jun;18(6):499-502
pubmed: 4337382
J Cardiol. 2016 Oct;68(4):308-15
pubmed: 26572956
Br Med J (Clin Res Ed). 1982 Oct 23;285(6349):1157-9
pubmed: 6812785
Eur J Clin Invest. 2015 Nov;45(11):1129-44
pubmed: 26268950
J Biol Chem. 2011 Aug 19;286(33):28715-22
pubmed: 21705322
J Am Soc Nephrol. 2019 Jun;30(6):1073-1085
pubmed: 31036759
Nihon Eiseigaku Zasshi. 1968 Dec;23(5):443-50
pubmed: 5752712
Am J Nephrol. 2009;29(6):582-91
pubmed: 19145073
Cardiovasc Res. 2011 Apr 1;90(1):165-70
pubmed: 21156821
FASEB J. 2008 Jul;22(7):2465-75
pubmed: 18256306
Kidney Int. 2014 Jan;85(1):142-50
pubmed: 23884339
J Bone Miner Res. 2011 Dec;26(12):2959-66
pubmed: 21887703
Expert Rev Mol Med. 2011 Mar 30;13:e11
pubmed: 21450123
Curr Hypertens Rep. 2012 Jun;14(3):228-37
pubmed: 22476974
J Am Soc Nephrol. 2008 Feb;19(2):213-6
pubmed: 18094365
Coron Artery Dis. 2015 Dec;26(8):678-85
pubmed: 26398149
Kidney Int. 2019 Jan;95(1):138-148
pubmed: 30442332